Compare NMAI & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMAI | LAB |
|---|---|---|
| Founded | 2021 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.5M | 354.1M |
| IPO Year | N/A | 2008 |
| Metric | NMAI | LAB |
|---|---|---|
| Price | $13.69 | $0.89 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 101.7K | ★ 2.0M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.63 |
| P/E Ratio | $21.30 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.31 | $0.87 |
| 52 Week High | $13.96 | $1.72 |
| Indicator | NMAI | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 69.14 | 35.40 |
| Support Level | $13.43 | N/A |
| Resistance Level | $13.90 | $1.39 |
| Average True Range (ATR) | 0.24 | 0.04 |
| MACD | 0.18 | 0.01 |
| Stochastic Oscillator | 98.55 | 18.13 |
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.